Mesa Laboratories, Inc.
NASDAQ:MLABHardware, Equipment & Parts
-$0.15 today
- Market cap
- $774.56M
- Beta
- 0.93
- P/E (TTM)
- 78.3
- EPS (TTM)
- $1.21
- Dividend yield
- 0.68%
Volume 0.07M
Average 0.16M
Big Five Numbers
Mesa Laboratories, Inc. growth analysis
Start with the long-run numbers that show whether MLAB compounds: return on capital and growth in sales, earnings, equity, and free cash flow.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | N/A | N/A | +92.4% | N/A |
Revenue | N/A | N/A | +4.4% | +3.4% |
Equity | N/A | N/A | -23.0% | +14.7% |
Cash | N/A | N/A | -6.5% | -1.4% |
ROIC | N/A | -12.3% | -20.2% | 2.8% |
Analysis
Latest growth is strongest in Equity at +14.7% and weakest in Cash at -1.4%. Three-year average ROIC is -20.2%, which helps show whether that growth is being earned efficiently.
Growth analysis
Is growth accelerating or fading?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +92.4% | N/A0 analysts |
| Revenue | N/A | N/A | +4.4% | +3.6% (3yr)1 analysts |
| Net Income | N/A | N/A | +93.3% | N/A1 analysts |
| EBIT | N/A | N/A | +77.3% | N/A — |
Analysis
Recent growth has been strongest in Net Income at +93.3% over three years. Forward estimates point to Revenue at +3.6% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Revenue segments
Where does the growth come from?
Break revenue down by product and geography to see which parts of the business drive the trend.
Revenue by segment
Where MLAB earns its revenue, as reported in company filings
- Sterilization and Disinfection Control
- Calibration Solutions
- Biopharmaceutical Development
- Clinical Genomics
- Product
- Service
- Other
| Segment · FY2026 | Revenue | Share | YoY |
|---|---|---|---|
| Sterilization and Disinfection Control | $101.57M | 40.8% | — |
| Calibration Solutions | $53.55M | 21.5% | — |
| Biopharmaceutical Development | $48.63M | 19.5% | — |
| Clinical Genomics | $45.39M | 18.2% | — |
Figures in USD. Smaller segments are grouped as "Other".
Free cash flow
Does growth turn into cash?
Check whether reported growth converts into free cash flow after capital spending.
Free Cash Flow
Net Income to FCF bridge
FY2026
Analysis
FY2026 free cash flow is $39.6M. FCF conversion is 589.7% of net income. Operating cash flow was $42.8M, with capex of -$3.3M. The largest bridge item is D&A at $23.3M.
Price targets
What do analysts expect from the price?
Compare the current price with the low, average, and high analyst targets.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for MLAB.
Analyst ratings
How do analysts rate the stock?
Review the buy, hold, and sell split and recent upgrades and downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
Unlock analyst ratings
Sign in free to see the buy/hold/sell breakdown and recent rating changes for MLAB.
Competitor growth
How does Mesa Laboratories, Inc. grow against peers?
Compare historical and forecast growth with similar companies.
Competitor Growth
Peer CAGR comparison & forward estimates
| Company | Market Cap | 10yr | 5yr | 3yr | Fwd |
|---|---|---|---|---|---|
Thermo Fisher Scientific Inc. TMO | $259.44B | +10.1% | +6.7% | -0.3% | +5.8% (5yr)15 analysts |
Agilent Technologies, Inc. A | $49.05B | +5.6% | +5.4% | +0.5% | +6.2% (5yr)2 analysts |
Revvity, Inc. RVTY | $17.24B | +3.1% | -5.5% | -4.8% | +4.6% (5yr)11 analysts |
Bio-Techne Corporation TECH | $11.44B | +9.3% | +5.5% | +2.2% | +10.1% (5yr)1 analysts |
Qiagen N.V. QGEN | $10.30B | +5.0% | +2.2% | -0.8% | +4.2% (5yr)6 analysts |
Bio-Rad Laboratories, Inc. BIO | $9.85B | +2.5% | +0.3% | -2.7% | +2.2% (5yr)1 analysts |
10x Genomics, Inc. TXG | $7.07B | — | +16.6% | +7.6% | +7.5% (5yr)5 analysts |
Maravai LifeSciences Holdings, Inc. MRVI | $1.13B | — | -8.1% | -40.5% | +8.1% (5yr)2 analysts |
Pacific Biosciences of California, Inc. PACB | $611.98M | +5.6% | +15.2% | +7.6% | +11.3% (5yr)3 analysts |
Standard BioTools Inc. LAB | $279.27M | -2.9% | -9.2% | -4.5% | +1.2% (4yr)1 analysts |
Questions
Growth questions
Common questions about MLAB's growth, answered from reported and forecast figures.
Is MLAB growing revenue?
Revenue grew 3.4% year over year, from $240.98M to $249.13M.
Is MLAB turning growth into profit?
The latest net margin is 2.7%, which shows how much revenue became net income.
Continue the stock analysis
Jump to another research area for this company.